

Supplementary tables

Supplementary Table 1. Bivariate analysis to assess possible relationships with mental health in axSpA patients by region

	Mean ± SD or n (%)									
	Europe		North America		Latin America		Asia		South Africa	
	GHQ-12 <3	GHQ-12 ≥3	GHQ-12 <3	GHQ-12 ≥3	GHQ-12 <3	GHQ-12 ≥3	GHQ-12 <3	GHQ-12 ≥3	GHQ-12 <3	GHQ-12 ≥3
Sociodemographic										
Age	47.6 ± 13.9*	42.6 ± 12.0*	45.7 ± 14.9*	43.2 ± 13.5*	44.8 ± 12.8	43.9 ± 10.9	40.3 ± 10.7*	36.7 ± 10.1*	47.5 ± 10.4*	43.5 ± 10.1*
Gender. Female	668 (51.8)*	1,257 (63.0)*	216 (61.4)	263 (63.1)	84 (42.2)*	223 (63.9)*	54 (18.7)	71 (22.8)	36 (81.8)	84 (82.4)
Educational level. University	655 (50.8)	946 (47.4)	217 (61.6)*	228 (54.5)*	109 (54.8)*	112 (32.1)*	89 (30.8)	93 (29.9)	20 (45.5)	34 (33.3)
Employment status										
Employed	675 (54.3)*	873 (46.3)*	215 (62.5)*	198 (50.3)*	106 (60.6)*	127 (40.8)*	118 (43.7)*	135 (52.5)*	31 (81.6)	72 (87.8)
Temporary sick leave	131 (10.5)*	316 (16.8)*	6 (1.7)*	22 (5.6)*	1 (0.6)*	35 (11.3)*	75 (27.8)*	54 (21.0)*	0 (0.0)	0 (0.0)
Permanent sick leave	98 (7.9)*	205 (10.9)*	17 (4.9)*	53 (13.5)*	1 (0.6)*	6 (1.9)*	3 (1.1)*	11 (4.3)*	0 (0.0)	0 (0.0)
Retired or early retired	152 (12.2)*	151 (8.0)*	67 (19.5)*	47 (11.9)*	34 (19.4)*	51 (16.4)*	57 (21.1)*	30 (11.7)*	0 (0.0)	2 (2.4)
Unemployed	44 (3.5)*	167 (8.9)*	17 (4.9)*	39 (9.9)*	15 (8.6)*	53 (17.0)*	1 (0.4)*	12 (4.7)*	1 (2.6)	2 (2.4)
Homemaker	125 (10.1)*	121 (6.4)*	11 (3.2)*	22 (5.6)*	14 (8.0)*	31 (10.0)*	12 (4.4)*	11 (4.3)*	4 (10.5)	3 (3.7)
Student	17 (1.4)*	51 (2.7)*	11 (3.2)*	13 (3.3)*	4 (2.3)*	8 (2.6)*	4 (1.5)	4 (1.6)*	2 (5.3)	3 (3.7)
Patient organization membership	580 (45.0)	8330 (41.6)	138 (39.2)	165 (39.5)	66 (33.2)	99 (28.4)	171 (59.2)*	159 (51.1)*	37 (84.1)	88 (86.3)
Lifestyles										
Realization of physical activity	1,129 (87.6)*	1635 (82.0)*	305 (86.9)	343 (82.9)	150 (78.1)	218 (75.2)	238 (83.2)*	231 (74.5)*	38 (88.4)	77 (75.5)
Smoking	226 (18.1)*	541 (27.9)*	38 (12.1)	99 (26.2)	22 (11.1)	33 (9.5)	52 (18.0)	65 (20.9)	8 (18.2)	12 (11.8)
Alcohol	487 (37.8)*	604 (30.3)*	127 (36.1)	160 (38.3)	38 (19.1)	45 (12.9)	50 (17.3)	56 (18.0)	17 (38.6)	28 (27.5)
Patient-reported outcomes										

Disease activity (0-10)	4.4 ± 2.0*	6.0 ± 1.8*	4.5 ± 2.1*	6.3 ± 1.9*	4.1 ± 2.6	6.4 ± 2.1*	4.1 ± 1.9*	5.7 ± 1.8*	5.3 ± 1.7*	6.3 ± 1.7*
Spinal Stiffness (3-12)	7.3 ± 2.5*	8.1 ± 2.4*	7.1 ± 2.3*	8.0 ± 2.2*	6.0 ± 2.5*	6.9 ± 2.6*	6.3 ± 2.3*	7.5 ± 2.4*	8.2 ± 1.7	8.7 ± 1.9
Functional Limitation (0-54)	15.5 ± 14.0*	22.0 ± 15.7*	19.9 ± 13.4*	25.7 ± 15.3*	14.1 ± 13.3*	21.5 ± 15.1*	11.1 ± 10.9*	16.4 ± 13.0*	15.9 ± 12.1	20.5 ± 13.3
Disease characteristics										
Diagnostic delay	7.7 ± 9.0	7.7 ± 8.7	9.1 ± 11.3	8.8 ± 10.8	5.5 ± 8.1	6.2 ± 8.8	3.9 ± 4.6	4.5 ± 6.1	13.8 ± 11.0*	9.5 ± 10.3*
Symptom duration	21.1 ± 14.9*	16.7 ± 12.4*	19.4 ± 15.4*	16.9 ± 13.3*	14.2 ± 11.4	13.4 ± 11.1	12.1 ± 9.3	11.1 ± 9.3	22.7 ± 12.7*	16.0 ± 12.2*
Extra-musculoskeletal manifestations										
Uveitis	285 (24.2)	384 (21.4)	97 (30.2)	118 (31.3)	36 (19.1)*	85 (28.3)*	58 (21.5)	73 (26.1)	11 (25.6)	23 (25.0)
Inflammatory bowel disease	132 (10.8)*	259 (13.9)*	46 (14.3)*	82 (21.6)*	25 (13.2)*	59 (20.3)*	45 (16.5)	43 (15.8)	11 (26.2)	22 (23.2)
Treatments										
NSAIDs	791 (76.0)	1,319 (77.4)	294 (83.8)	339 (81.7)	180 (90.9)	310 (89.6)	214 (75.9)	224 (73.7)	42 (95.5)	94 (94.0)
csDMARDs	385 (37.6)	644 (38.6)	127 (36.5)	178 (43.3)	130 (65.7)	226 (65.3)	152 (55.5)	146 (49.3)	30 (71.4)	81 (82.7)
bDMARDs	476 (45.0)	787 (46.1)	210 (59.7)	266 (63.6)	139 (69.8)	220 (63.0)	111 (38.4)	111 (35.7)	20 (45.5)	42 (41.2)

* Statistically significant differences (p<0.05)